Biotech: The Next Pricing Controversy?

Piper Jaffray's Joshua Schimmer note that co-pay assistance programs that help patients afford expensive drugs and are used by companies like Amgen ( AMGN ), Biogen ( BIIB ), Incyte ( INCY ), Celgene ( CELG ), and Gilead Sciences ( GILD ) are in the news once again--and that's not necessarily a good thing. He explains: